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Abstract
Background: The use of technology to support health and health care has grown rapidly in the last decade across all ages and
medical specialties. Newly developed eHealth tools are being implemented in long-term management of growth failure in children,
a low prevalence pediatric endocrine disorder.
Objective: Our objective was to create a framework that can guide future implementation and research on the use of eHealth
tools to support patients with growth disorders who require growth hormone therapy.
Methods: A total of 12 pediatric endocrinologists with experience in eHealth, from a wide geographical distribution, participated
in a series of online discussions. We summarized the discussions of 3 workshops, conducted during 2020, on the use of eHealth
in the management of growth disorders, which were structured to provide insights on existing challenges, opportunities, and
solutions for the implementation of eHealth tools across the patient journey, from referral to the end of pediatric therapy.
Results: A total of 815 responses were collected from 2 questionnaire-based activities covering referral and diagnosis of growth
disorders, and subsequent growth hormone therapy stages of the patient pathway, relating to physicians, nurses, and patients,
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parents, or caregivers. We mapped the feedback from those discussions into a framework that we developed as a guide to integration
of eHealth tools across the patient journey. Responses focused on improved clinical management, such as growth monitoring and
automation of referral for early detection of growth disorders, which could trigger rapid evaluation and diagnosis. Patient support
included the use of eHealth for enhanced patient and caregiver communication, better access to educational opportunities, and
enhanced medical and psychological support during growth hormone therapy management. Given the potential availability of
patient data from connected devices, artificial intelligence can be used to predict adherence and personalize patient support.
Providing evidence to demonstrate the value and utility of eHealth tools will ensure that these tools are widely accepted, trusted,
and used in clinical practice, but implementation issues (eg, adaptation to specific clinical settings) must be addressed.
Conclusions: The use of eHealth in growth hormone therapy has major potential to improve the management of growth disorders
along the patient journey. Combining objective clinical information and patient adherence data is vital in supporting decision-making
and the development of new eHealth tools. Involvement of clinicians and patients in the process of integrating such technologies
into clinical practice is essential for implementation and developing evidence that eHealth tools can provide value across the
patient pathway.
(J Med Internet Res 2021;23(5):e27446) doi: 10.2196/27446
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Introduction
eHealth Implementation
The implementation of eHealth solutions in clinical practice is
growing rapidly [1]. Digitalization of the health sector is
bringing many opportunities, such as the collection of
patient-generated data [2] and the provision of health services
over distance, also known as telehealth [3]. These technological
advances are supporting a paradigm shift towards more
integrated health care [4]. However, implementing technologies
in the highly complex setting of health care delivery faces many
challenges, which include both technical and human factors (eg,
organizational issues, service integration, usability, legal
frameworks, privacy) [5].
Opportunities of eHealth for Patient Empowerment
in Growth Hormone Therapy
Pediatric endocrinology (the management of endocrine disorders
in children) has adopted eHealth solutions for decades. For
example, diabetes mellitus education uses game-based
interventions [6,7], and more recent advanced technologies,
such as augmented reality [8] and robotics [9], have been
integrated into education and assistive care in diabetes mellitus.
These approaches have traditionally looked at chronic conditions
that require intensive lifestyle modifications, where lack of
adherence to medication has a negative impact, with an
increased risk of health complications and hospitalization.
Similarly, one of the areas that may benefit from implementation
of novel eHealth tools is the long-term use of growth hormone
therapy in the management of childhood growth failure. Growth
hormone therapy is indicated for a heterogeneous set of growth
disorders; in addition to growth hormone deficiency, approved
pediatric indications include Turner syndrome, short stature
after being born small for gestational age, Noonan syndrome,
Prader-Willi syndrome, SHOX (short stature
homeobox-containing gene) deficiency, chronic renal failure,
and idiopathic short stature, although licensed indications vary
by country and growth hormone formulations [10,11].
Importantly, growth hormone affects not only growth of
children, but also metabolism, cardiovascular health, bone
strength, and quality of life in the short and long term [12-14].
These effects continue into adult life, and a proportion of
patients treated as children continue to require growth hormone
therapy as adults. During the transition from pediatric to adult
care, eHealth tools have been shown to be important in
supporting patients to achieve positive outcomes and enhance
ongoing engagement with health care [15,16].
The case of growth hormone therapy is somewhat different from
that of diabetes because patients do not require intensive or
large-scale lifestyle modifications. Because growth hormone
therapy is administered by daily injection, the most important
self-management behavior is adherence to medication, which
affects long-term outcome. Growth hormone therapy for children
with short stature must be administered consistently and with
a high level of adherence over many years for an effective gain
in height and optimal adult height [17]. Therapy is required
from early childhood to adolescence; therefore, support and
involvement of the patient’s family and caregivers are crucial
to achieving the best outcomes. Thus, eHealth tools to support
growth hormone therapy must be developed with a holistic
approach that involves the family and must also take into
consideration physiological, psychological, and developmental
changes as children grow, with a view to using these tools over
many years [18,19]. Additionally, some of the conditions that
are supported with growth hormone therapy are classified as
rare diseases (incidence <1 in 2500 [20]), posing extra
challenges. Physicians’ knowledge may be limited, which can
often lead to delayed referral and diagnosis, and the small
number of patients creates difficulties in collection of data to
generate large and meaningful data sets unless performed on
an international scale. The collection of adherence data is of
crucial importance [21] to optimizing adherence and improving
adult height [22,23].
An optimal adult height is attained through the early recognition
and understanding of the different causes of growth failure, thus
leading to early referral, diagnosis, and growth hormone therapy
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initiation. As mapped out in Figure 1, outcomes can be improved
at all stages of the patient journey through comprehensive
monitoring of growth, education, and clinical support to achieve
a high level of therapy adherence. We surmised that eHealth
tools could play a significant role in the management of growth
disorders and growth hormone therapy through additional and
comprehensive support and monitoring.
Figure 1. Patient journey for children with growth failure and those who receive growth hormone therapy. GH: growth hormone; GP: general practitioner;
HSDS: height standard deviation score; Ht: height; HV: height velocity; IGF-1: insulin-like growth factor-1; PSP: pediatric specialist physician; SDS:
standard deviation score.
Objective
We aimed to develop a framework for using eHealth tools in
the identification, investigation and diagnosis of growth failure
and the management of growth hormone therapy in pediatric
patients. Development of this framework was carried out as a
multistep process, guided by the principles of participatory
research involving key informants across a series of workshops
and virtual activities. Similar approaches have been widely
applied in medical informatics to identify implementation
challenges of digital health tools [24], including the application
of the Delphi method [25] in other endocrine disease areas [26]
and eHealth for pediatrics [27].
Methods
Initially, we conducted 3 online webinars with presentations
and interactive discussions around key concepts and issues of
eHealth, including data science and use in pediatric patients
with growth failure and growth hormone therapy. Based on
active involvement in this initial step, a group of 12 participants
were subsequently invited to more detailed discussions. This
report describes the approach that was adopted for these online
detailed discussion workshops and is outlined (Figure 2) and
explained in more detail in the following sections.
The 12 participants were pediatric endocrinologists who have
experience in the treatment of growth disorders. Convenience
sampling was used to select participants on the basis of previous
participation, interest or experience in eHealth activities, and
patients’use of connected injection devices for growth hormone
therapy. Sampling also considered participants on the basis of
providing worldwide geographical representation, with
participants from Argentina, Brazil, Finland, France, Germany,
Malaysia, Sweden, Spain, Taiwan, and the United Kingdom,
encompassing a wide base of health care and socioeconomic
conditions. The participants completed preparation activities
that included reading relevant publications [28-30],
brainstorming activities (see Multimedia Appendix 1), and
completing an adapted version of the eHealth literacy scale
(eHEALS) survey [31] related to digital health literacy (see
Multimedia Appendix 2).
The brainstorming activities solicited opinions of the participants
on opportunities, challenges, and established or potential eHealth
tools relating to 3 stakeholder groups: (1) pediatric
endocrinologists, (2) patients and their parents/caregivers, and
(3) nurses. Simultaneously, the pediatric endocrinologists
completed a survey about their perception of eHealth tools in
aiding clinical decisions and their confidence in use of such
tools, with results quantified as proportions of respondents
agreeing or disagreeing with the statements on a 5-point scale.
The brainstorming activities and surveys were designed using
the SurveyMonkey tool (SVMK Inc).
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Figure 2. Workshop participation methodological steps. Each step was carried out twice, first in relation to referral and diagnosis stages and second
in relation to all stages from growth hormone therapy initiation to completion.
For the first online workshop, the physicians completed the
brainstorming exercise and eHealth literacy questionnaire with
respect to the first part of the patient journey (Figure 1), through
referral and diagnosis. For the second online meeting, the
exercise and questionnaire were completed with respect to the
subsequent stages of the patient journey from start of growth
hormone therapy, through monitoring, tracking, and assessment
of outcomes, to either growth hormone discontinuation or into
the transition phase from pediatric to adult care for patients still
requiring growth hormone therapy.
In each case, the brainstorming responses were initially
categorized according to common themes, which were then
discussed in the online workshops under the moderation of PD
who was the key facilitator and with additional availability of
textual responses. The brainstorming responses for each of the
3 categories of opportunities, challenges, and eHealth tools were
finally categorized as relating to process, clinical pathway
(including diagnostics for the first meeting), or education. These
3 main categories reflected important aspects for the
implementation of eHealth solutions in clinical practice and
formed the basis for the framework for best practices: (1)
process—responses that related to everyday tasks that aided the
distance and time logistics required by the specified people for
delivery of health care; (2) clinical—responses relating to the
medical condition, including those relating to establishing
diagnosis; and (3) education—responses relating to digital
technologies that can enhance learning and understanding of
the condition, and therapy for either health care specialists or
the patients and families.
Results
Survey Responses
A total of 815 responses were received from the 2 brainstorming
exercises, comprising 419 in relation to referral and diagnosis
stages and 396 relating to growth hormone therapy stages. In
each case, the responses were grouped and categorized; Figure
3 shows the grouped responses relating to physicians for the
referral and diagnosis stages, while Figure 4 shows the growth
hormone therapy stages (responses relating to
patients/parents/caregivers can be found in Multimedia
Appendix 3 for referral/diagnosis and Multimedia Appendix 4
for growth hormone therapy, and responses relating to nurses
in Multimedia Appendix 5 for referral/diagnosis and Multimedia
Appendix 6 for growth hormone therapy). In the following
subsections we describe the responses provided, assigned to
each group in turn.
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Figure 3. Physician viewpoints regarding referral and diagnosis stages of pediatric patients with growth failure. Where no comments box is shown,
clinicians did not provide any opinions relating to that category. HCP: health care provider.
Figure 4. Physician viewpoints regarding growth hormone therapy initiation, monitoring, and transition. Where no comments box is shown, clinicians
did not provide any opinions relating to that category. GH: growth hormone; IGF-1: insulin-like growth factor-1.
Brainstorming Responses Relating to Physicians
Growth Monitoring and Screening
For the referral and diagnosis stages, the perceived opportunities
for physicians largely concerned process, particularly regarding
digital reminders to record growth. It was noted that this could
be done by primary care personnel, such as in Finland where
children’s height is routinely monitored and data immediately
entered and integrated into electronic health records. Machine
learning or artificial intelligence algorithms could be used to
identify faltering growth and be followed by notification of
health care professionals of this issue. Although such a system
may overestimate referrals, it could support earlier diagnosis
of conditions such as Turner syndrome and SHOX deficiency;
it was noted that physicians may lack knowledge of these types
of conditions, and pediatricians may not readily associate signs
or symptoms with a diagnosis, resulting in late referral and
therapy delay. Algorithms that have been developed to follow
through symptomatic characteristics to identify the cause of
growth failure could be incorporated into eHealth tools to aid
physicians through the early stages of the referral and diagnostic
process. Streamlining the screening, referral, and diagnostic
process may expedite subsequent genetic testing, particularly
for rare conditions associated with growth failure, thus
identifying patients eligible for growth hormone therapy at an
earlier stage.
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At each stage of the patient journey, during referral, diagnosis,
and monitoring of response to growth hormone therapy, the
ability to accurately measure height electronically was cited as
a significant area of development that could overcome the
labor-intensive challenge of manually measuring height and
inputting this into the patient record. There is potential for height
and height velocity to be determined using electronic devices,
such as mobile phones or tablet computers, which could be used
by health professionals and parents or caregivers. Development
of digital techniques for height measurement outside of the
clinic would be very helpful in countries with remote rural
communities where primary care is lacking, and data could be
incorporated directly by linking to electronic health records. A
tool that could be used by patients or caregivers to measure
height electronically and be linked to artificial intelligence-based
technology could increase the frequency of height measurements
and provide a signal to health care providers about faltering
growth to support earlier intervention.
Growth Hormone Response Prediction Models
The response to growth hormone therapy can be determined
using validated prediction models that estimate potential adult
height by incorporating parameters related to growth. These
parameters include bone age, which is a determination of
skeletal physiological maturity relative to chronological age
through use of hand radiographs that can be evaluated with an
automated digital method. There are multiple prediction models
and a current lack of consensus regarding which of these is the
gold standard. Clinicians wished to see a more unified
international approach to growth prediction, which could
subsequently lead to the incorporation of a model into an
eHealth platform to aid clinicians in determining adult height.
Incorporation of prediction models into apps was considered a
challenge, particularly given the lack of consensus on which
model to use. It was, however, considered to be an important
tool to allow identification of those patients who would most
benefit from growth hormone therapy. Moreover, by using a
digital device to measure height and then linking this to an
electronic patient record, adult height prediction could be
provided in a more seamless way through the integration of a
prediction model into the process.
Communication, Logistics, and Engagement
Remote Delivery of Care and Communication
Communication between primary care and pediatric endocrine
specialists, and others in multidisciplinary teams, was identified
as an opportunity for eHealth tools to improve service provision.
Multidisciplinary teams require good videoconferencing
facilities; current platforms require improvements, such as
increased bandwidth, to facilitate greater use of telemedicine.
Guidelines for physicians that augment their ability to carry out
online consultations are required, and education facilities for
this could be provided through online workshops and video
recordings.
One of the biggest challenges mentioned was constraints of
time and distance when patients have to attend a hospital or
clinic in order for assessments to be made. This may involve
considerable travel over long distances (particularly for those
in rural settings) and a large amount of time for both patients
and health care personnel to ensure that appointments can be
initiated and kept. Thus, the refinement of telecommunication
systems will help to overcome this barrier.
Participants proposed that electronic health records could be
used for automating appointments, referrals, and data reporting.
As consultations improve efficiency, more information could
be made available for each patient, giving interoperability
greater importance in order that data entry does not require
additional time. Overall, eHealth tools need to be efficient to
use if they are to gain acceptance.
Patient Engagement
Digital technologies that can seamlessly record adherence with
the therapy regimen allow of evaluation and timely intervention
if adherence decreases over time. Adding adherence data to
growth prediction models was considered a potential aid to the
assessment of patients that would benefit from therapy and
could be used as an additional variable in prediction of adult
height.
Interactive games that motivate and engage the patient may also
increase the long-term adherence to growth hormone therapy,
and their development requires involvement of families, nurses,
and physicians as key stakeholders.
Psychological Well-Being
One challenge for physicians is dealing with the psychological
impact of growth hormone therapy. As patients move through
different stages of their therapy journey, with evolving physical
and emotional maturity, variations in therapy adherence are
expected. Digital tools to evaluate the psychological status of
patients could enable the identification and assessment of
anxiety related to the condition and long-term therapy.
Participants suggested that therapy-related psychology could
be assessed using short online questionnaires, with
standardization across different clinics. In addition, as online
and digital tools are developed to deliver psychological
interventions, these could be used to support patient care, thus
reinforcing therapy adherence.
Evaluation of psychological status is particularly important at
the end of pediatric care when patients who remain growth
hormone–deficient transition to adult care in order to continue
growth hormone therapy to optimize benefits of therapy beyond
growth. Digital tools can be used to explain the pathway changes
and specific needs to children and young adults, and can also
provide feedback to refine care pathways.
Safety Assessments
Medical devices should also enable and encourage safety, with
mechanisms built into the reporting platforms to individualize
according to the specific diagnosis, therapy device, and
condition of the patient. The reporting mechanism for safety
concerns needs to be carefully considered to determine who
should receive and respond to reports. Physicians could also be
alerted to any problems in order to differentiate between
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background symptoms of the condition and adverse events
potentially related to therapy.
Brainstorming Exercise Responses From the
Patient/Parent/Caregiver Perspective
Patient Education
Physician perspectives on opportunities and eHealth tools
relating to patients, parents, or caregivers predominantly focused
on education, largely concerning patient awareness, access to
trusted information, and increased remote training.
Videoconferencing tools are already being used for this to some
extent, but more online tools involving apps, websites, medical
portals, and search resources are needed to provide information
that is accurate, trustworthy (ie, endorsed or produced by
reputable sources with knowledge in the area), and easily
understood. These tools could also be used to increase access
to and interaction with health care personnel; however, access
may need to be limited to avoid out-of-hours timing, but this
could be mitigated by use of technologies such as virtual
assistants or “chatbots ” to provide automated answers.
Patient-Reported Outcomes
Digital techniques to accurately measure height at home would
enable growth to be monitored without the need for clinical
review. These methods could also detect growth deceleration,
with integration into electronic health records and prompting
alerts sent to patients, parents, or caregivers. Therapy-related
anxiety and psychological problems could be aided through
games to generate interest in diagnosis and therapy, and to
reduce needle anxiety. Appropriate tools could be developed to
enhance psychological care, although it was noted that language
barriers and digital access problems would need to be overcome
to avoid digital exclusion and polarization of patients.
Behavioral management may be enhanced through educational
tools with a holistic approach, incorporating factors such as
good nutrition and exercise to improve metabolic and physical
outcomes beyond growth.
Brainstorming Exercise Responses From the Clinic
Nurse Perspective
Responses in regard to nurses, similar to those from physicians,
were more often related to process, including support for
adherence, and on the medical devices used for therapy delivery.
These patient-support tasks are frequently the responsibility of
specialized nurses. Difficulties were noted in the delivery of
roles, including patient testing, education. and ongoing support,
which could be made easier by improved digitalization of and
access to records, telemedicine technologies, and remote
monitoring; eHealth tools could relieve nurses of some duties,
yielding more time for personal interaction with the patient.
Responses also indicated challenges in the receipt and delivery
of training and education to nurses around the management of
growth failure and therapy, with limited opportunities for
learning. In some counties, clinics do not have specialist nurses,
and responsibilities may be inadequately defined, with no clear
career paths. In such situations, online interactive learning
resources could support training.
During growth hormone therapy, virtual reality or augmented
reality immersive experiences could help with training and
distraction during injections and blood sampling. During
transition from pediatric to adult care, digital tools can assist
nurses in providing psychological support and education for
patients.
eHealth Literacy Survey
The questionnaire results indicated that the majority of the
participants felt that eHealth tools were useful, but some were
uncertain about evidence for their usefulness. There was also
some uncertainty about what eHealth tools are currently
available and how to use them. Most felt that digital tools are
important and that they had the skills to use them, but many
lacked confidence in their use largely due to the perceived lack
of evidence. The respondents indicated that more data on the
effectiveness of eHealth tools need to be presented for
mainstream use in clinical practice, and interoperability would
be required for routine clinical use.
Pediatric Growth Disorders and Growth Hormone
Therapy Management Framework
From the workshop and questionnaire information, we devised
a framework for developing eHealth tools for growth disorders
and growth hormone therapy, as shown in Figure 5. The
framework was devised to support integration of new eHealth
tools into health care systems and assist health care
professionals, patients, and families throughout the patient
journey.
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Figure 5. Framework for managing pediatric growth disorders and growth hormone therapy mapped to the patient journey. AR/VR: augmented
reality/virtual reality; HCP: healthcare provider.
Discussion
Principal Findings
We are not aware of any similar studies and, to the best of our
knowledge, this is the first time global experts in pediatric
endocrinology have come together to consider possible eHealth
solutions for the care of children and young people with growth
disorders. Our work has led to greater understanding of the
acceptability, confidence, and knowledge of the use of eHealth
tools in growth disorders, and has opened up digital health care
options to improve current clinical management.
Several key themes arose, which were aligned across the themed
stakeholder groups considered: physicians,
patients/parents/caregivers, and nurses. It was agreed that
communication through established and novel technologies are
likely to provide significant opportunities to improve interactions
between clinicians across the health sector and to facilitate
diagnosis, referral, and patient management. Importantly,
telecommunication has the potential to improve management
of patients who may be in isolated communities or rural areas
remote to the central health care provider and to enable parents
and caregivers to rapidly communicate with health care
professionals when problems arise [32]. Connected digital
systems will reduce travel time for families and reduce time of
missed education, in turn supporting cost and efficiency savings
for families and health services [33]. Integration of these systems
into electronic patient records would optimize this process.
Additionally, physicians suggested that parents and caregivers
would value electronic processes to help them manage
appointments, that administration tasks should be automated,
and that improved interoperability between systems and within
and across centers would allow sharing and integration of vital
patient information.
Rapid development of technology could also facilitate the earlier
identification of growth disorders through electronic screening
programs, with the proviso that the input of height data is
accurate. Thus, the development of a mobile phone or
tablet-based tool that can accurately measure height in the home
environment and that could link with a centralized electronic
system may accelerate the identification and referral of patients
with short stature and poor growth, reducing the prevalence of
late diagnosis of rare disorders of growth where other
comorbidities may exist [34-36]. However, a reliable electronic
system for early identification of growth disorders is complex
and will depend on the integration of systems that monitor height
at home and in the clinical environment, with a high sensitivity
and specificity [37].
Once a diagnosis of growth failure has been established, an
accurate and validated digital tool to monitor height will provide
a means of assessing response to growth hormone therapy.
Response to growth hormone therapy and improved adherence
are both predictors of adult height [23,38,39]. Fundamental to
this is the use of artificial intelligence to understand and analyze
patient growth data, which can be fed into an electronic health
record. When patients become established on growth hormone,
clinicians would value a unified means of predicting adult
height, encompassing the diverse growth prediction models
currently available [40-43]; identifying the impact of growth
hormone through prediction models on digital platforms that
link to or are embedded in patient records can aid optimization
of therapy.
Education was identified as a key area to which eHealth tools
could add significant value. Physicians, nurses, and families
(including the patients) require relevant and trusted information
delivered in an engaging, and developmentally and
professionally appropriate way to support the rapid acquisition
in knowledge [44,45]. Recent advances in medical education
for patients and clinicians have focused on using immersive
virtual and augmented reality (AR/VR), app-based interactive
training, virtual assistants to answer questions in real-time, 3D
modeling, and online real-time education [8,46,47]. In particular,
virtual assistants or chatbots have been identified as a technology
suitable for supporting patient groups with focused information
available in real time [48-50]. One of the challenges in using
novel technology-based education is ensuring that hard-to-reach
and vulnerable groups have appropriate access to and
understanding of these tools [51,52].
Participants also suggested that eHealth tools could be developed
to support adherence to growth hormone therapy through the
identification of therapy-related psychological and medical
issues, potentially via access to data on patient-reported outcome
measures [53] or ecological momentary assessments [54]. Given
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the psychological and physiological changes that take place
during growth and puberty, these tools will need to be versatile
and responsive, supporting patients and their families during
the transition from pediatric to adult health care settings [55];
furthermore, to mitigate the risk of future health complications,
such tools need to reiterate education and prevent disengagement
from health care [15,16,56]. Importantly, eHealth tools were
also cited as an option to address some of the psychological
issues identified, with digital platforms providing online
psychological support; technologies including VR or AR could
provide a means of reducing anxiety during painful procedures
such as growth hormone injections, similar to the application
of VR and AR as distraction tools in other conditions
[8,46,56,57].
Although there was clear support for eHealth solutions to
address challenges in the diagnosis and management of patients
with growth disorders, results from the e-literacy questionnaire
identified a need to ensure that the development and
implementation of these tools is supported by a well-established
evidence base and that integration within a clinical or
home-based setting is supported by education and training.
The workshops and questionnaires have provided information
that has led us to devise a framework to support the development
of eHealth tools for growth disorders, which may also be
relevant to other long-term conditions. The framework (Figure
5) has been devised as an eHealth overlay for the patient journey
from identification of a problem, to diagnosis, implementation
of therapy, and subsequent monitoring and support. The
framework maps directly onto the patient pathway and thus will
provide the relevant context for those developing novel
technologies. It will support appropriate service and health care
integration of new eHealth tools for health care professionals,
patients, and families, which in turn will provide reassurance
that technology development has appropriately addressed unmet
needs for growth disorders.
Limitations
Participants in this study were chosen for their experience in
childhood growth disorders and active interest and involvement
in use of eHealth tools. However, participation was limited to
physicians, albeit with significant experience in this field of
medicine; thus, the views relating to patients, parents, caregivers,
and nurses may be skewed by personal reflections and opinions,
but responses were perhaps more directed and uniform. The
relatively small number that provided responses and opinions
may not be wholly representative of the pediatric endocrine
community although they represented a wide geographical
distribution, allowing us to consider the variation in health care
systems in different countries. Due to logistic reasons,
face-to-face meetings were not ideal, and we decided to conduct
the workshops online, which might have restricted some
activities that could have been better conducted through a
face-to-face format. Although all participants were highly
experienced pediatric endocrinologists, their differing
backgrounds meant that there was an inherent variation in
cultural perspectives, health care system setups, funding
arrangements, and governmental priorities; however, this broad
range of experiences could be viewed as reflective of real-world
scenarios. Despite all participants having a strong interest in
the use of digital techniques, eHealth tools may sometimes be
seen to be purely theoretical, as they encompass technologies
that could potentially be devised but are not yet established.
The integration and adoption of our proposed eHealth
framework into clinical practice remains to be assessed and
rigorously tested in future studies.
Conclusions
By bringing together established and experienced pediatric
endocrinologists from across the world, we have developed a
framework for the implementation and integration of eHealth
tools to support the identification and ongoing referral of
children with growth disorders, and the subsequent management
and monitoring of growth hormone therapy. Integration of
eHealth tools in the management of patients with growth
disorders will support height screening and regular height
monitoring; improve communication; facilitate the delivery of
and access to training and education for health care providers,
patients, parents, and caregivers; improve therapy adherence;
enable the earlier identification of problems; and support patients
and families during their journey. Digitalization can enhance
the collection of data from multiple sources to support research
in low prevalence diseases, such as those treated with growth
hormone, to build on best practice by providing an additional
incentive for research collaboration using eHealth tools. The
use of eHealth tools in the patient pathway has the potential to
increase efficiency in care delivery while introducing cost
benefits. The involvement of both service providers and service
users is of crucial importance for the successful design and
implementation of eHealth solutions. The credibility of these
eHealth tools will be dependent on appropriate clinical
evaluation of established and emerging digital tools. Moreover,
training health care professionals and patients and their families
in the use of eHealth tools while ensuring successful service
integration and ongoing support will prevent the misuse or
rejection of eHealth tools and unintended negative health
consequences.
We conclude that novel eHealth tools have considerable
potential for supporting patients and their families, and for health
care providers in the detection and management of growth
disorders. We envisage that our work may provide a blueprint
for other chronic conditions that could benefit from eHealth
tools in supporting long-term adherence.
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